Evidence over ego: how Australian private digital weight-loss services need to respond to continual scepticism from prominent medical bodies

The case for evidence-led digital obesity care

Private digital weight-loss services (PDWLSs) in Australia are operating under sustained scrutiny from prominent medical bodies, and this commentary argues that the right response is not a media dispute, but a research agenda.

Published in the Series of Endocrinology, Diabetes and Metabolism, this commentary by researchers at the University of Sydney and Eucalyptus identifies the three core concerns that Australian primary care organisations have repeatedly raised against PDWLSs, and sets out a clear blueprint for how providers can, and must, address them through peer-reviewed evidence.

"Until PDWLSs provide real-world evidence [of their quality and safety], the medical industry's scepticism of the modality should and will continue."

What the sceptics are saying

Three recurring concerns from Australian medical bodies

Over the past several years, a consistent set of criticisms has emerged in the arguments of Australian primary care organisations against PDWLSs. The commentary notes that these criticisms tend to be applied broadly across the sector, making no distinction between low-quality providers that offer little more than a script for weight-loss medication and higher-quality services that deliver personalised, multidisciplinary care on an ongoing basis.

The three recurring themes are:

• PDWLSs prioritise business interests over healthcare standards. Critics have drawn comparisons between digital weight-loss services and fast food chains, arguing that convenience and commercial incentives are incompatible with quality long-term care.
• PDWLSs compromise prescription safety standards. Sceptics argue that without a longitudinal patient record, face-to-face assessment, and two-way clinical communication, prescribing decisions in digital settings are inherently less safe than those made in traditional GP consultations.
• PDWLSs fragment care and disregard the importance of care continuity. The absence of a known local GP, one familiar with a patient's broader health, family and community context, is cited as a meaningful gap in the holistic management of a chronic condition like obesity.

The opportunity and the obligation

The commentary argues that rather than contesting these criticisms in the media, PDWLSs should treat them as a research blueprint. Each concern maps directly to a type of evidence that could and should be generated.

To address prescribing safety concerns, providers should publish peer-reviewed analyses of medication prescribing and dispensing error rates, supported by transparent documentation of their clinical governance processes. To demonstrate care continuity, quantitative data on MDT contact frequency, app engagement and patient satisfaction would provide meaningful benchmarks. And to counter the accusation of prioritising short-term commercial outcomes, PDWLSs should invest in sustainability research, publishing long-term outcome data that follows patients beyond their active treatment period.

The commentary also identifies a broader research question that the field has not yet adequately addressed: understanding why patients are choosing PDWLSs over face-to-face alternatives, and the degree to which digital modalities genuinely mitigate access barriers to obesity care rather than simply offering a more convenient path to medication.

Australia's obesity problem is growing, and access barriers to quality care are a significant part of the reason. Digital care models have the potential to address those barriers, but only if providers build the evidence base to justify the trust that patients and the medical community are being asked to place in them.